1
|
Ackland SP, Michael M, Souza P, Martin JH, Clarke SJ, Francis K, Karapetis CS, Gurney H. Science and art of
anticancer
drug dosing: nine steps to personalised therapy. Intern Med J 2020. [DOI: 10.1111/imj.14948] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Affiliation(s)
- Stephen P. Ackland
- Faculty of Health and MedicineUniversity of Newcastle Newcastle New South Wales Australia
- Department of Medical OncologyCalvary Mater Newcastle Newcastle New South Wales Australia
- Hunter Medical Research Institute Newcastle New South Wales Australia
| | - Michael Michael
- Department of Medical OncologyPeter MacCallum Cancer Centre Melbourne Victoria Australia
| | - Paul Souza
- School of MedicineUniversity of Wollongong Wollongong New South Wales Australia
| | - Jennifer H. Martin
- Hunter Medical Research Institute Newcastle New South Wales Australia
- Centre for Human Drug Research, School of Medicine and Public Health, Faculty of Health and MedicineUniversity of Newcastle Newcastle New South Wales Australia
| | - Stephen J. Clarke
- Department of Medical OncologyRoyal North Shore Hospital Sydney New South Wales Australia
- Sydney Medical SchoolUniversity of Sydney Sydney New South Wales Australia
| | - Kay Francis
- Medical Oncology Group of Australia Sydney New South Wales Australia
| | - Christos S. Karapetis
- Medical Oncology Group of Australia Sydney New South Wales Australia
- Flinders Centre for Innovation in CancerFlinders University and Flinders Medical Centre Adelaide South Australia Australia
| | - Howard Gurney
- Crown Princess Mary Cancer CentreWestmead Hospital Sydney New South Wales Australia
- Faculty of Medicine and Health SciencesMacquarie University Sydney New South Wales Australia
| |
Collapse
|
2
|
Strojan P, Vermorken JB, Beitler JJ, Saba NF, Haigentz M, Bossi P, Worden FP, Langendijk JA, Eisbruch A, Mendenhall WM, Lee AWM, Harrison LB, Bradford CR, Smee R, Silver CE, Rinaldo A, Ferlito A. Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: A systematic review. Head Neck 2015; 38 Suppl 1:E2151-8. [PMID: 25735803 DOI: 10.1002/hed.24026] [Citation(s) in RCA: 109] [Impact Index Per Article: 12.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/25/2015] [Indexed: 01/12/2023] Open
Abstract
BACKGROUND The optimal cumulative dose and timing of cisplatin administration in various concurrent chemoradiotherapy protocols for nonmetastatic head and neck squamous cell carcinoma (HNSCC) has not been determined. METHODS The absolute survival benefit at 5 years of concurrent chemoradiotherapy protocols versus radiotherapy alone observed in prospective randomized trials reporting on the use of cisplatin monochemotherapy for nonnasopharyngeal HNSCC was extracted. In the case of nonrandomized studies, the outcome results at 2 years were compared between groups of patients receiving different cumulative cisplatin doses. RESULTS Eleven randomized trials and 7 nonrandomized studies were identified. In 6 definitive radiotherapy phase III trials, a statistically significant association (p = .027) between cumulative cisplatin dose, independent of the schedule, and overall survival benefit was observed for higher doses. CONCLUSION Results support the conclusion that the cumulative dose of cisplatin in concurrent chemoradiation protocols for HNSCC has a significant positive correlation with survival. © 2015 Wiley Periodicals, Inc. Head Neck 38: E2151-E2158, 2016.
Collapse
Affiliation(s)
- Primož Strojan
- Department of Radiation Oncology, Institute of Oncology, Ljubljana, Slovenia
| | - Jan B Vermorken
- Department of Medical Oncology, Antwerp University Hospital, Edegem, Belgium
| | - Jonathan J Beitler
- Departments of Radiation Oncology, Otolaryngology, and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia
| | - Nabil F Saba
- Department of Hematology and Medical Oncology, The Winship Cancer Institute of Emory University, Atlanta, Georgia
| | - Missak Haigentz
- Department of Medicine, Division of Oncology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York
| | - Paolo Bossi
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - Francis P Worden
- Department of Internal Medicine, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan
| | - Johannes A Langendijk
- Department of Radiation Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
| | - Avraham Eisbruch
- Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan
| | | | - Anne W M Lee
- Center of Clinical Oncology, University of Hong Kong - Shenzhen Hospital, Shenzhen, China
| | - Louis B Harrison
- Department of Radiation Oncology, Beth Israel Medical Center and St Luke's-Roosevelt Hospitals, New York, New York
| | - Carol R Bradford
- Department of Otolaryngology-Head and Neck Surgery, University of Michigan, Ann Arbor, Michigan
| | - Robert Smee
- Department of Radiation Oncology, The Prince of Wales Cancer Centre, Sydney, New South Wales, Australia
| | - Carl E Silver
- Departments of Surgery and Otolaryngology-Head and Neck Surgery, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York
| | | | - Alfio Ferlito
- University of Udine School of Medicine, Udine, Italy
| |
Collapse
|
3
|
Rivera F, Vega-Villegas ME, López-Brea MF, García-Castaño A, de Juan A, Collado A, Galdós P, Rubio A, del Valle A, Rama J, Sanz-Ortiz J. Long-Term Results of a Phase II Trial of Induction Chemotherapy with Uracil-Ftegafur (UFT), Vinorelbine, and Cisplatin (UFTVP) followed by Radiotherapy Concomitant with UFT and Carboplatin (RT/UFTJ) in a Primary Site Preservation Setting for Resectable Locally Advanced Squamous Cell Carcinoma of Larynx and Hypopharynx. Laryngoscope 2004; 114:1163-9. [PMID: 15235341 DOI: 10.1097/00005537-200407000-00006] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
OBJECTIVE We present long-term results of a phase II trial of induction chemotherapy (IC) with uracilftegafur (UFT) 200 mg/m orally days 1 to 21, vinorelbine 25 mg/m intravenously (IV) days 1 and 8, and cisplatin 100 mg/m IV day 1 (UFTVP) each for 21 days for 4 courses, followed by radiotherapy concomitant with UFT 100 mg/m orally daily and carboplatin (area under the curve [AUC] = 0.5 IV weekly) (RT/ UFTJ), without surgery to the primary site if response, in patients (pts) with resectable locally advanced squamous cell carcinoma of the larynx and hypopharynx. The primary endpoint was clinical complete response (CR) to induction UFTVP, and secondary endpoints were long-term overall survival (OS) and survival with primary site preservation (SPP). RESULTS Between 1994 and 1997, 37 pts were included. CR to IC was 54% (95% confidence interval [CI] 43-65%). Main toxicity of UFTVP was G 3,4 neutropenia (73% of pts, 16% developed febrile neutropenia). After IC, primary site was treated with RT in 29 pts: 20 of them received RT/UFTJ (main toxicity mucositis G 3,4 70%). No pt died during treatment. Actuarial 5-year OS and SPP were 57% and 37%, respectively. CONCLUSIONS This approach has significant activity and acceptable toxicity for achieving promising long-term OS and SPP and deserves further investigation.
Collapse
Affiliation(s)
- Fernando Rivera
- Department of Medical Oncology, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Hosokawa Y, Kamada T, Shirato H, Ohmori K, Yasuda M, Yahata H, Nishioka T, Kitahara T, Arimoto T, Inuyama Y. Simultaneous carboplatin and radiotherapy for all stages of head and neck squamous cell carcinoma. Clin Oncol (R Coll Radiol) 1995; 7:168-72. [PMID: 7547519 DOI: 10.1016/s0936-6555(05)80510-2] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
The study investigated the toxicity and efficiency of the concomitant administration of radiotherapy and carboplatin to patients with head and neck carcinomas. Sixty-three patients with head and neck squamous cell carcinomas, other than nasopharyngeal cancer and Stage I (UICC) laryngeal cancers, were treated by external radiotherapy and four courses of carboplatin at a dose of 100 mg/m2 per week. In two patients, only three courses were possible due to renal toxicity. In the other 61 patients, toxicities were self-limiting and no patient required interruption of carboplatin administration. No patient required discontinuation of radiotherapy because of acute toxicity. Of 61 evaluable patients, a complete response (CR) was obtained in 11.5% and a partial response (PR) in 60.7% at 40 Gy. In 41 patients treated to 65 Gy (including two patients with maxillary sinus carcinoma, who were treated by debulking surgery), CR was obtained in 76.9% and CR+PR was 100% at the end of treatment. The actuarial survival rate of the 63 patients at 2 years was 69.2%, with a median follow-up period of 24.4 months. One of 12 patients who received salvage surgery after radical radiotherapy has died due to poor wound healing after the surgery. The schedule was safe, providing a weekly check of serum samples was possible. It is likely that the rate of local control and vocal cord preservation in laryngeal tumours might improve if concurrent carboplatin is used. Careful follow-up is required to determine the long-term effect of concomitant carboplatin administration.
Collapse
Affiliation(s)
- Y Hosokawa
- Department of Dental Radiology, School of Dentistry, Hokkaido University, Sapporo, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|